Overview

Tacrolimus for Thrombocytopenia in SS

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Hydroxychloroquine
Tacrolimus